☆ 4.5 News Item

PROSTATE CANCER To screen or not to screen?

NATURE REVIEWS UROLOGY (2009)

Journal

NATURE REVIEWS UROLOGY

Volume 6, Issue 6, Pages 299-301

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/nrurol.2009.92

Keywords

-

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Physics, Multidisciplinary

Phonon Self-Energy Corrections: To Screen, or Not to Screen

Jan Berges, Nina Girotto, Tim Wehling, Nicola Marzari, Samuel Ponce

Summary: The study evaluated the accuracy of two approaches in estimating phonon spectral functions and low-temperature phonon dispersions. It found that the approximate method yielded excellent corrections at low computational cost, while using a bare vertex could in theory improve results but was challenging in practice. An alternative strategy based on downfolding to partially screened phonons and interactions was proposed as a natural scheme to include electron-electron interactions and tackle phonons in strongly correlated materials.

PHYSICAL REVIEW X (2023)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Women 75 Years Old or Older: To Screen or Not to Screen?

Cindy S. Lee, Alana Lewin, Beatriu Reig, Laura Heacock, Yiming Gao, Samantha Heller, Linda Moy

Summary: Screening mammography should be continued for women aged 75 and older as it has higher sensitivity, specificity, cancer detection rate, and positive predictive values in this population. Early detection of breast cancer in older women reduces invasive treatment and mortality risks. Shared decision making and consideration of individual values, overall health status, and comorbidities are important in guiding screening decisions for this age group.

RADIOGRAPHICS (2023)

Add to Collection

Review Oncology

To bind or not to bind: Cistromic reprogramming in prostate cancer

Michelle Shen, Lea-Kristine Demers, Swneke D. Bailey, David P. Labbe

Summary: The cistrome of key regulatory factors in prostate cancer, including the androgen receptor (AR) and other transcription factors, is substantially reprogrammed during disease progression. The SWI/SNF complex and the chromatin-modifying helicase CHD1 also play important roles in this process.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer

Takuya Tsujino, Kazumasa Komura, Teruo Inamoto, Haruhito Azuma

Summary: In recent years, advances in omics technology and CRISPR/Cas9 technology have improved the identification of genes associated with cancer diseases, providing opportunities for the discovery of new therapeutic targets. This knowledge plays a crucial role in clinicians' decision-making regarding patient treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

To screen or not to screen medical students for carriage of multidrug-resistant pathogens?

E. Smelikova, P. Drevinek, O. Nyc, M. Brajerova, J. Tkadlec, M. Krutova

Summary: This study investigated the carriage of multidrug-resistant pathogens among medical students and found that a percentage of students carried resistant strains. The study also found a negative association between nasal carriage of Staphylococcus aureus and antibiotic and probiotic consumption, and a higher detection rate among students in contact with livestock.

JOURNAL OF HOSPITAL INFECTION (2023)

Add to Collection

Article Clinical Neurology

Metachromatic leukodystrophy: To screen or not to screen?

An I. Jonckheere, Sandra D. K. Kingma, Francois Eyskens, Victoria Bordon, Anna C. Jansen

Summary: Metachromatic leukodystrophy (MLD) is a neurodegenerative disorder caused by gene mutations. Treatment options vary based on age and symptoms at onset, with allo-HSCT being the traditional choice. However, the outcomes are inconsistent and new treatment options are being explored. Newborn screening for MLD is becoming important in the changing therapeutic field.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2023)

Add to Collection

Article Oncology

To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer

Wee Loon Ong, Patrick Cheung, Hans Chung, William Chu, Jay Detsky, Stanley Liu, Gerard Morton, Ewa Szumacher, Chia-Lin Tseng, Danny Vesprini, Melanie Davidson, Ananth Ravi, Merrylee Mcguffin, Liying Zhang, Alexandre Mamedov, Andrea Deabreu, Meghan Kulasingham-Poon, Andrew Loblaw

Summary: This study aimed to investigate the efficacy of 2-fraction SABR +/- DIL boost in prostate cancer patients. The results showed that DIL boost had similar medium-term efficacy (in 4yrPSARR and BF), with impact on late urinary QOL outcomes.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Add to Collection

Review Oncology

Intraductal Carcinoma of the Prostate: To Grade or Not to Grade

Jerasit Surintrspanont, Ming Zhou

Summary: Intraductal carcinoma of the prostate (IDC-P) is a distinct tumor type that has significant implications on clinical outcomes and patient management. There is ongoing debate about whether IDC-P should be factored into the Grade Group (GG) of prostate cancer grading. Different urological societies have conflicting recommendations, causing confusion for pathologists and clinicians.

CANCERS (2023)

Add to Collection

Article Biochemical Research Methods

Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer

Ruidong Li, Shibo Wang, Yanru Cui, Han Qu, John M. Chater, Le Zhang, Julong Wei, Meiyue Wang, Yang Xu, Lei Yu, Jianming Lu, Yuanfa Feng, Rui Zhou, Yuhan Huang, Renyuan Ma, Jianguo Zhu, Weide Zhong, Zhenyu Jia

Summary: This study utilized genomic selection and omics data, particularly the BLUP model and BLUP-HAT method, to predict the prognosis of prostate cancer. The results indicated that these methods performed well in increasing the reliability of outcome prediction.

BRIEFINGS IN BIOINFORMATICS (2021)

Add to Collection

Article Immunology

B cells and cancer: To B or not to B?

Wolf Herman Fridman, Florent Petitprez, Maxime Meylan, Tom Wei-Wu Chen, Cheng-Ming Sun, Lubka T. Roumenina, Catherine Sautes-Fridman

Summary: Recent studies have suggested that B cells in the tumor microenvironment may play a significant role in presenting tumor-associated antigens to T cells and producing antibodies that enhance antigen presentation, ultimately impacting cancer clinical outcomes. Immune complexes formed by B cells can also have deleterious effects through inflammation, angiogenesis, and immunosuppression via macrophage and complement activation.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Chemistry, Analytical

Baclofen: To Screen or Not to Screen in Postmortem Blood?

Limon Khatun Nahar, Kevin G. Murphy, Sue Paterson

Summary: The study investigated the prevalence and concentrations of Baclofen in Coroners' toxicology, as well as its association with other drug misuse in causing death. Results showed that although some misuse of Baclofen occurred, deaths are rare.

JOURNAL OF ANALYTICAL TOXICOLOGY (2021)

Add to Collection

Article Clinical Neurology

MR Brain Screening in ADPKD Patients To Screen or not to Screen?

I Capelli, M. Zoli, M. Righini, L. Faccioli, V Aiello, L. Spinardi, D. Gori, F. Friso, A. Rustici, C. Bortolotti, C. Graziano, V Mantovani, N. Sciascia, D. Mazzatenta, M. Seri, M. Pastore Trossello, G. La Manna

Summary: This study retrospectively analyzed ADPKD patients who underwent brain MRI screening between 2016 and 2019. The results showed a higher prevalence of IA in ADPKD patients compared to non-ADPKD population.

CLINICAL NEURORADIOLOGY (2022)

Add to Collection

Article Oncology

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines

Lukas Donix, Holger H. H. Erb, Claudia Peitzsch, Anna Dubrovska, Manuel Pfeifer, Christian Thomas, Susanne Fuessel, Kati Erdmann

Summary: This study aimed to investigate the influence of acquired resistance against ionizing radiation or docetaxel chemotherapy on cisplatin tolerance in metastatic castration-resistant prostate cancer (mCRPC) cell line models. The results indicate that previous radiotherapy may moderate sensitization to cisplatin, while docetaxel resistance does not affect cisplatin tolerance. Different mCRPC cell lines exhibit significant variability regarding cisplatin tolerance.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Geriatrics & Gerontology

To screen or not to screen for osteoporosis amongst post-menopausal women with one prior osteoporotic fracture in Greece

Kyriakos Souliotis, Christina Golna, Paul Golnas, Ioannis-Anestis Markakis, Polyzois Makras

Summary: Background screening and linkage to care for osteoporosis is insufficient in Greece, with only a small percentage of postmenopausal women receiving proper care. This study aims to estimate the impact of comprehensive screening on future fracture burden among women with prior osteoporotic fracture in Greece. The results show that increased screening can lead to reductions in deaths and fractures, but it also comes with increased costs.

AGING CLINICAL AND EXPERIMENTAL RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Biologic Therapy in HIV: To Screen or Not to Screen

Willam Davis, Ilan Vavilin, Nidhi Malhotra

Summary: Biologic therapy has revolutionized the treatment of chronic inflammatory diseases, but it is crucial to rule out prior infection of chronic hepatitis B virus and tuberculosis before initiating therapy. In this case, a patient receiving treatment for Crohn's disease was found to have undiagnosed HIV, progressing to AIDS.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Integrative & Complementary Medicine

Moderate to Substantial Inter-Rater Reliability in the Assessment of Cranial Bone Mobility Restrictions

Kyla Demers, Chantal Morin, Louise Collette, Richard DeMont

Summary: The study found that there was a moderate reliability for lateral strain of the SOS, substantial reliability for other SOS strain patterns, and almost perfect reliability for temporal, parietal, and frontal bone mobility assessments when evaluated by three experienced osteopaths. The results emphasize the importance of consensus training and rigorous methodology in manual therapy reliability studies.

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2021)

Add to Collection

Article Oncology

Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials

Maria Antonietta Gambacorta, Carlotta Masciocchi, Giuditta Chiloiro, Elisa Meldolesi, Gabriella Macchia, Johan van Soest, Fenke Peters, Laurence Collette, Jean-Pierre Gerard, Samuel Ngan, C. Claus Roedel, Andrea Damiani, Andre Dekker, Vincenzo Valentini

Summary: The optimal timing of surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer remains controversial. A study found that lengthening the surgical interval had a favorable impact on achieving a pathological complete response, with the best results seen at a 10-week interval.

RADIOTHERAPY AND ONCOLOGY (2021)

Add to Collection

Article Mathematical & Computational Biology

Correcting the bias of the net benefit estimator due to right-censored observations

Julien Peron, Maryam Idlhaj, Delphine Maucort-Boulch, Joris Giai, Pascal Roy, Laurence Collette, Marc Buyse, Brice Ozenne

Summary: Generalized pairwise comparisons are used in randomized clinical trials to analyze multiple prioritized outcomes simultaneously. A correction method has been proposed to estimate the contribution of uninformative pairs based on the average contribution of informative pairs. The correction does not affect the power or type-1 error of tests based on Delta, and is most useful when the proportion of censored observations is close to 70%.

BIOMETRICAL JOURNAL (2021)

Add to Collection

Review Medicine, General & Internal

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Katharina Beyer, Lisa Moris, Michael Lardas, Anna Haire, Francesco Barletta, Simone Scuderi, Eleni Vradi, Giorgio Gandaglia, Muhammad Imran Omar, Steven MacLennan, Jihong Zong, Bahman Farahmand, Sara J. Maclennan, Zsuzsanna Devecseri, Alex Asiimwe, Laurence Collette, Anders Bjartell, James Ndow, Alberto Briganti, Mieke Van Hemelrijck

Summary: This research project aims to explore the relationship between current diagnostic and prognostic factors for prostate cancer and clinical outcomes through a systematic literature review and expert panel discussion. The ultimate goal is to develop an online tool to present the identified factors and make them accessible to all stakeholders, with no ethical implications involved.

BMJ OPEN (2021)

Add to Collection

Article Oncology

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

Silke Gillessen, Nicolas Sauve, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A. Gietema, Ugo De Giorgi, Fay H. Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert A. Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier Garcia-Del-Muro, Daniel Y. C. Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene Negaard, Christian Fankhauser, Jonathan Shamash, David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, Jorg Beyer

Summary: This study updated and adjusted the classification of metastatic nonseminomatous germ cell tumors, providing a more detailed and personalized assessment of patient prognosis. The new prognostic model identified a new cutoff value for lactate dehydrogenase, increasing age, and the presence of lung metastases as additional adverse prognostic factors.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

Jorg Beyer, Laurence Collette, Nicolas Sauve, Gedske Daugaard, Darren R. Feldman, Torgrim Tandstad, Alexey Tryakin, Olof Stahl, Enrique Gonzalez-Billalabeitia, Ugo De Giorgi, Stephane Culine, Ronald de Wit, Aaron R. Hansen, Marko Bebek, Angelika Terbuch, Costantine Albany, Marcus Hentrich, Jourik A. Gietema, Helene Negaard, Robert A. Huddart, Anja Lorch, Fay H. Cafferty, Daniel Y. C. Heng, Christopher J. Sweeney, Eric Winquist, Michal Chovanec, Christian Fankhauser, Daniel Stark, Peter Grimison, Andrea Necchi, Ben Tran, Axel Heidenreich, Jonathan Shamash, Cora N. Sternberg, David J. Vaughn, Ignacio Duran, Carsten Bokemeyer, Anna Patrikidou, Richard Cathomas, Samson Assele, Silke Gillessen

Summary: The classification of IGCCCG has been a major advancement in the management of germ-cell tumors, but a modern series of 2,451 men with metastatic seminoma treated between 1990 and 2013 showed significant improvement in progression-free survival and overall survival compared to the original data. The original IGCCCG classification remains relevant, but can be further refined by adding LDH at a cutoff of 2.5x upper limit of normal as an additional adverse prognostic factor.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis

M. Sharabiani, E. Clementel, N. Andratschke, L. Collette, C. Fortpied, V. Gregoire, J. Overgaard, J. Willmann, C. Hurkmans

Summary: The study aimed to externally validate NTCP models for g3OM. Results showed good performance of the models, indicating their validity across different treatment techniques and patient characteristics.

RADIOTHERAPY AND ONCOLOGY (2021)

Add to Collection

Article Oncology

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Benjamin Lacas, Alexandra Carmel, Cecile Landais, Stuart J. Wong, Lisa Licitra, Jeffrey S. Tobias, Barbara Burtness, Maria Grazia Ghi, Ezra E. W. Cohen, Cai Grau, Gregory Wolf, Ricardo Hitt, Renzo Corvo, Volker Budach, Shaleen Kumar, Sarbani Ghosh Laskar, Jean-Jacques Mazeron, Lai-Ping Zhong, Werner Dobrowsky, Pirus Ghadjar, Carlo Fallai, Branko Zakotnik, Atul Sharma, Rene-Jean Bensadoun, Maria Grazia Ruo Redda, Severine Racadot, George Fountzilas, David Brizel, Paolo Rovea, Athanassios Argiris, Zoltan Takacsi Nagy, Ju-Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Auperin, Pierre Blanchard, Jean-Pierre Pignon

Summary: The updated results of the study demonstrate the significant improvement in overall survival for head and neck cancer patients with the addition of concomitant chemotherapy, particularly for those with stage III or IV disease. Induction or adjuvant chemotherapy showed less benefit in increasing overall survival. Additionally, efficacy decreases with age progression.

RADIOTHERAPY AND ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer A Secondary Analysis of 2 Randomized Clinical Trials

Martin T. King, Ming-Hui Chen, Laurence Collette, Anouk Neven, Michel Bolla, Anthony V. D'Amico

Summary: The association of PSA failure with outcomes may differ between locally advanced and localized prostate cancer, suggesting the potential benefit of treatment intensification with novel antiandrogen agents for locally advanced disease following PSA failure.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy

Conny Vrieling, Samson Y. Assele, Lotte Moser, Nicolas Sauve, Saskia Litiere, Alain Fourquet, Philip Poortmans, Henk Struikmans, Geertjan van Tienhoven, Harry Bartelink, Laurence Collette

Summary: The study analyzed the prognostic impact of isolated local recurrence (ILR) in early-breast cancer patients treated with breast-conserving therapy, and found that the cumulative breast cancer mortality rates after ILR varied depending on the timing of ILR. A multistate model was able to predict long-term outcomes based on individual patient characteristics.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Urology & Nephrology

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

Yasmin Abu-Ghanem, Johannes V. van Thienen, Christian Blank, Maureen J. B. Aarts, Michael Jewett, Igle Jan de Jong, Jean-Baptiste Lattouf, Harm H. E. van Melick, Lori Wood, Peter Mulders, Sylvie Rottey, John Wagstaff, Patricia Zondervan, Tom Powles, Anouk Neven, Laurence Collette, Bertrand Tombal, John Haanen, Axel Bex

Summary: The post hoc analysis of the SURTIME trial data showed that patients in the deferred nephrectomy arm had a higher percentage of receiving sunitinib compared to the immediate nephrectomy arm, and they also had a more profound reduction of target lesions. Starting with systemic therapy may impair the administration, onset, and duration of sunitinib in comparison to the deferred approach, potentially leading to early and more profound disease control.

BJU INTERNATIONAL (2022)

Add to Collection

Review Urology & Nephrology

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

Sarah Burdett, D. J. Fisher, C. L. Vale, J. F. Tierney, N. W. Clarke, M. K. B. Parmar, C. N. Sternberg, M. Stoeckle, J. Lehmann, U. E. Studer, R. W. Sonntag, F. M. Torti, S. Groshen, A. V. Bono, P. J. Goebell, F. Cognetti, R. J. Cote, S. Groshen, L. Collette, C. N. Sternberg, A. I. Rolevich, A. G. Zhegalik

Summary: The systematic review and meta-analysis support the use of adjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer, showing significant improvement in overall and recurrence-free survival rates. The findings suggest that this treatment option is beneficial in improving outcomes for patients with this condition.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease

Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Demetrios Andreopoulos, Antoine Engelen, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Karine Peignaux-Casasnovas, Jihane Boustani, Fernanda G. Herrera, Bradley R. Pieters, Annerie Slot, Amit Bahl, Christopher D. Scrase, David Azria, Jan Jansa, Joe M. O'Sullivan, Alphonsus C. M. Van den Bergh, Laurence Collette

Summary: The study showed that 6 months of concurrent and adjuvant androgen suppression can significantly improve event-free survival and disease-free survival in intermediate-risk prostate cancer patients treated with irradiation at 74 or 78 Gy, but did not significantly impact overall survival and distant metastasis-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review

Katharina Beyer, Lisa Moris, Michael Lardas, Anna Haire, Francesco Barletta, Simone Scuderi, Megan Molnar, Ronald Herrera, Abdul Rauf, Riccardo Campi, Isabella Greco, Kirill Shiranov, Saeed Dabestani, Thomas van den Broeck, Sujenthiran Arun, Mauro Gacci, Giorgio Gandaglia, Muhammad Imran Omar, Steven MacLennan, Monique J. Roobol, Bahman Farahmand, Eleni Vradi, Zsuzsanna Devecseri, Alex Asiimwe, Jihong Zong, Sara J. Maclennan, Laurence Collette, James NDow, Alberto Briganti, Anders Bjartell, Mieke Van Hemelrijck

Summary: The study aims to explore diagnostic and prognostic factors related to prostate cancer and evaluate their reliability and applicability. The results indicate that most of the factors identified need further evaluation and validation before they can be recommended for use in clinical practice.

BMJ OPEN (2022)

Add to Collection

Article Health Care Sciences & Services

Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry

Anouk Neven, Marissa C. van Maaren, Kay Schreuder, Ries Kranse, Henk Struikmans, Philip M. Poortmans, Harry Bartelink, Laurence Collette, Lifang Liu, Sabine Siesling

Summary: This study evaluated the representativeness of Dutch patients participating in the European Organization for Research and Treatment of Cancer EORTC boost-no-boost trial to the target breast cancer patient population. The results showed that trial participants had similar baseline characteristics and overall survival rates compared to non-trial participants. Data linkage can bridge the gap between research and clinical practice.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.